Progress toward molecular therapy for diabetes mellitus: A focus on targeting inflammatory factors

Diabetes mellitus (DM) has been the most prevalent global metabolic disease, turning into a serious risk for human health. Several researches have recorded a role for inflammation and immunity in the pathogenesis of both in T1DM and in T2DM. Lots of chemical agents are available to control and to cu...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2022-07, Vol.189, p.109945-109945, Article 109945
Main Authors: Dehghan, Mohadesse, Ghorbani, Fateme, Najafi, Sajad, Ravaei, Neda, Karimian, Maede, Kalhor, Kambiz, Movafagh, Abolfazl, Mohsen Aghaei Zarch, Seyed
Format: Article
Language:English
Subjects:
Diabetes Mellitus
Inflammatory factors
Molecular Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diabetes mellitus (DM) has been the most prevalent global metabolic disease, turning into a serious risk for human health. Several researches have recorded a role for inflammation and immunity in the pathogenesis of both in T1DM and in T2DM. Lots of chemical agents are available to control and to cure diabetic patients, which are not always sufficient for euglycemia maintenance and late stage diabetic complications avoidance. Therefore, newborn therapeutic methods to refine clinical outcomes in DM are required. Nucleic-acid-based therapy also known as gene expression level regulator within the target cells has been calculated to be promising in various diseases. Thus, pronounced attempts have been dedicated to develop new targeted molecular therapy aimed at improving insulin resistance in DM. This review mainly focuses on recent progress in DM molecular therapy and whether, has potential efficacy against inflammatory mediators involved in DM.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2022.109945